


Difficult to Treat Depression


A Carlat Guide



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com



Chris Aiken, MD

DIFFICULT TO TREAT DEPRESSION


FIRST EDITION

Chris Aiken, MD

Editor in Chief
The Carlat Psychiatry Report

Director
Psych Partners

Adjunct Assistant Professor
Department of Psychiatry
New York University Langone
Wake Forest University



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Difficult to Treat Depression
FIRST EDITION

Published by Carlat Publishing, LLC
PO Box 626, Newburyport, MA 01950


Publisher and Editor-in-Chief: Daniel J. Carlat, MD
Deputy Editor: Talia Puzantian, PharmD, BCPP
Senior Editor: Ilana Fogelson

All rights reserved. This book is protected by copyright.

This CME/CE activity is intended for psychiatrists, psychiatric nurses, psychologists, and other health care professionals with an interest in mental health. The Carlat CME Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Carlat CME Institute maintains responsibility for this program and its content. Carlat CME Institute designates this enduring material educational activity for a maximum of twelve [12] AMA PRA Category 1 Credits™. Physicians or psychologists should claim credit commensurate only with the extent of their participation in the activity. The American Board of Psychiatry and Neurology has reviewed the Geriatric Psychiatry Fact Book and has approved this program as part of a comprehensive Self-Assessment and CME Program, which is mandated by ABMS as a necessary component of maintenance of certification. CME tests must be taken online at www.thecarlatreport.com/cme (for ABPN SA course subscribers).

To order, visit www.thecarlatreport.com
or call (866) 348-9279

Print: 979-8-9998818-1-6
eBook: 979-8-9893264-6-4



PRINTED IN THE UNITED STATES OF AMERICA

Sample Pages


Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

To Kellie Newsome

*Special thanks to Daniel Carlat, Owen Muir, and
Michael Sikorav for reviewing the manuscript*

Illustrations by Eleanor Aiken




Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Table of Contents

SECTION I: INTRODUCTION	1
Chapter 1: What is “Difficult-to-Treat” Depression?	3
Chapter 2: A Primer on “Regular” Depression.	5
SECTION II: ASSESSMENT AND DIAGNOSIS	11
<i>Common Causes of Treatment Resistance</i>	13
Chapter 3: Misdiagnosis	15
Chapter 4: Optimal Use of Assessment Tools	19
<i>Personalized Treatment for Depressive Subtypes</i>	25
Chapter 5: Bipolar Depression	27
Chapter 6: Depression with Mixed Features.	44
Chapter 7: Psychotic Depression	49
Chapter 8: Vascular Depression	56
Chapter 9: Inflammatory Depression	61
Chapter 10: Trauma and Depression.	66
Chapter 11: Other Subtypes of Depression	74
SECTION III: TREATMENT	83
<i>Psychosocial Treatment</i>	85
Chapter 12: The Psychology of Depression	87
Chapter 13: Working with Chronic Depression.	96
Chapter 14: Therapy and Lifestyle.	100
<i>Biological Treatment.</i>	115
Chapter 15: When Antidepressants Don’t Work.	117
Chapter 16: Monoamine Oxidase Inhibitors (MAOIs).	122
Chapter 17: Tricyclics	131
<i>Pharmacologic Augmentation.</i>	139
Chapter 18: Overview of Pharmacologic Augmentation.	140




Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Third-Line Augmentation Strategies	189
Chapter 24: Amantadine	191
Chapter 25: D-Cycloserine	195
Chapter 26: Minocycline	200
Rapid-Acting Medications	205
Chapter 27: Overview of Rapid-Acting Medications	206
Chapter 28: Alprazolam and the Benzodiazepines	208
Chapter 29: Eszopiclone.....	213
Chapter 30: Auvelity	217
Chapter 31: The Ketamines.....	221
Chapter 32: Pindolol	230
Chapter 33: Zuranolone	233
Chapter 34: Psychedelics	239
Natural Therapies and Deficiency States	245
Chapter 35: Overview of Natural Therapies and Deficiency States ..	247
Chapter 36: Light Therapy.....	250
Chapter 37: Folate, L-Methylfolate, and SAMe	256
Chapter 38: Vitamin D	261
Chapter 39: Omega–3 Fatty Acids.....	264
Chapter 40: Probiotics	270
Neuromodulation	275
Chapter 41: Overview of Neuromodulation.....	277
Chapter 42: Transcranial Magnetic Stimulation (TMS)	279
Chapter 43: Electroconvulsive Therapy (ECT)	285
Other Treatments	291
Chapter 44: Reproductive Hormones	293
Deprescribing	301
Chapter 45: Overview of Deprescribing	302
Chapter 46: Deprescribing Extra Antidepressants	306



Sample Pages


Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Index	331
--------------------	-----

LIST OF TABLES

Table 1-1. Common Features of Difficult-to-Treat Depression	4
Table 2-1. Choosing an Initial Antidepressant Based on Clinical Features	7
Table 4-1. Patient Health Questionnaire-2 (PHQ-2)	21
Table 4-2. General Symptom Scale	21
Table 5-1. Aiken's Structured Interview for Mania and Hypomania.	33
Table 5-2. Structured Bipolar Interview: Ambiguous Answers	35
Table 7-1. Screening for Psychotic Depression.	51
Table 8-1. Signs of Vascular Depression	57
Table 8-2. Nimodipine Summary	60
Table 9-1. Risk Factors for Inflammation	62
Table 9-2. Treatments for Inflammatory Depression	64
Table 10-1. Prazosin Summary	72
Table 11-1. The Neurotic Temperament	75
Table 11-2. Opposing Symptoms: Melancholic vs Atypical Depression	76
Table 11-3. Causes of Anxious Depression	77
Table 11-4. Augmentation Strategies for Depressive Subtypes	81
Table 14-1. Lifestyle and Depression: A Patient Guide	101
Table 14-2. Mediterranean Diet for Depression.	109
Table 14-3. Reasons for Inaction	112
Table 15-1. Optimal Dose Ranges for Second-Generation Antidepressants	120
Table 16-1. MAOI Antidepressants.	125
Table 16-2. Medications that Can Cause Serotonin Syndrome with MAOIs	127
Table 16-3. A Modernized MAOI Diet.	129
Table 17-1. Tricyclic Antidepressants: Comprehensive Guide	134
Table 17-2. The Human Cost of Anticholinergic Drugs.	135




Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Table 20-3. FDA Warnings with Antipsychotics	168
Table 21-1. Pramipexole Summary	175
Table 22-1. Triiodothyronine Summary.....	183
Table 23-1. Celecoxib Summary.....	187
Table 24-1. Amantadine Summary	194
Table 25-1. D-Cycloserine Summary	198
Table 26-1. Minocycline Summary	202
Table 27-1. Rapid-Acting Medications for Depression	207
Table 28-1. Alprazolam Summary	211
Table 29-1. Eszopiclone Summary.....	215
Table 30-1. Auvelity Summary	220
Table 31-1. Ketamine Summary.....	229
Table 32-1. Pindolol Summary	232
Table 33-1. Zuranolone Summary.....	236
Table 34-1. Psilocybin Summary	243
Table 35-1. Summary of Natural Therapy Evidence	248
Table 36-1. Light Therapy Summary.....	254
Table 37-1. Predictors of L-Methylfolate Response	258
Table 37-2. L-Methylfolate Summary.....	259
Table 38-1. Vitamin D Summary	262
Table 39-1. Omega-3 Fatty Acids Summary.....	268
Table 39-2. Recommended Omega-3 Products	268
Table 40-1. Probiotics Summary	273
Table 41-1. Neuromodulation and Interventional Psychiatry:	
What to Expect.....	278
Table 44-1. Treatment of Menopausal Symptoms.....	294
Table 44-2. Contraindications to HRT.....	295
Table 44-3. Estrogen in Psychiatry (OCP and HRT).....	297
Table 44-4. Risks of Testosterone Supplementation.....	298
Table 45-1. Withdrawal Symptoms by Medication Class	304
Table 46-1. Tapering Doses and Liquid Conversions	



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)


Purchase your copy with full access online at
www.thecarlatreport.com

LIST OF FIGURES

Figure 5-1. DSM Spectrum of Mood Disorders.....	28
Figure 5-2. Risk of antidepressant-induced mania/hypomania.....	29
Figure 8-1. Age-Related Prevalence of Vascular Depression.....	57
Figure 12-1. Neurons Under Stress.....	88
Figure 12-2. Neurons After Treatment.....	88
Figure 12-3. Antidepressant and Placebo Response Varies by Psychiatrist	94
Figure 14-1. Blue Light Suppresses Melatonin.....	105
Figure 15-1. Chance of Response to a Second Antidepressant Trial	118
Figure 15-2. Response and Side Effects by SSRI Dose	119
Figure 36-1. Positioning the Lightbox.....	253

LIST OF SCREENERS

Screeners 5-1. Rapid Mood Screener II	31
Screeners 5-2. Bipolar Spectrum Diagnostic Scale	32
Screeners 5-3. The Bipolarity Index.....	37
Screeners 10-1. Trauma and Depression Screener	66




Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

SECTION I

Introduction



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

CHAPTER 1


What is “Difficult-to-Treat” Depression?

MOST CLINICIANS KNOW THE FRUSTRATION: A patient with depression starts an antidepressant, maybe two, and doesn’t get better. You switch, you augment, and still—limited progress. You start to wonder if you’re missing something. You are not alone.

The term “treatment-resistant depression” (TRD) is meant to describe these cases—specifically, when two adequate trials of antidepressants fail. But that term is both too broad and too narrow. It lumps together patients who need completely different approaches (like someone with bipolar spectrum features vs someone with vascular depression), and it leaves out patients who respond initially and then relapse, or who never had a clean starting point to define an “episode.”

This book was born out of a need for a better way to think about these cases.

In 2002, a group of researchers gathered in San Francisco and coined a new term: Difficult-to-Treat Depression. They saw depression not as an acute illness to cure, but as a chronic condition to manage—more like diabetes than pneumonia. The goal was to improve function and quality of life, not to chase elusive symptom remission.



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

This guide is organized to mirror the clinical approach. We begin with assessment and diagnostic challenges (Part I), then move through various treatment modalities, from psychosocial interventions to pharmacology, natural therapies, and neuromodulation (Part II). You won't find one algorithm that works for every case in these pages. What you will find is a new way of thinking—more flexible, more practical, and more collaborative. We'll take a hard look at the data—and at our own habits and expectations as clinicians.


If you've ever found yourself wondering “*Now what?*” when faced with a patient who isn't getting better, this book is for you.

NOTE:

Although I prefer the term *difficult-to-treat depression*, I occasionally use the more specific term *treatment-resistant depression* when referring to patients who did not have a meaningful response to two or more antidepressant trials.

TABLE 1-1. Common Features of Difficult-to-Treat Depression

Long duration of illness	Medical and psychiatric comorbidities
Frequent recurrence	Suicide risk
Incomplete recovery	Soft bipolar features
Multiple treatment failures	Early childhood adversity
Periods of disability and hospitalizations	



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

CHAPTER 2

A Primer on “Regular” Depression

BEFORE WE DIVE into difficult-to-treat depression, let’s make sure we’re not skipping the basics. Many cases that end up with that dreaded label are simply undertreated—poor dosing, rushed switches, no measurement, or just a failure to look under the hood. This chapter walks through a practical, real-world approach to treating “regular” depression—starting with a good evaluation and ending with a thoughtful treatment plan.

The Evaluation

The workup for depression begins before a prescription is written. Depression is not one illness—it’s a syndrome. To treat it effectively, we need to ask: *Why is this person depressed?*


A thorough initial evaluation includes:

Timeline

Clarify the onset, duration, and course of the current episode. Ask about prior episodes, past treatments, and whether the patient recovered fully in the past or remained symptomatic between episodes.

Syndrome differentiation

- Do they meet DSM-5 criteria for major depressive disorder?
- Check for bipolar disorder, psychiatric comorbidities, and medical



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Psychosocial context

Assess recent stressors, trauma history, interpersonal conflict, and protective factors.

The Treatment Plan

Once you've confirmed a diagnosis, the next step is a treatment plan—not just a prescription.

Set expectations

Many patients (and clinicians) underestimate how long it takes for treatment to work. Antidepressants usually take 2–6 weeks for initial effects and up to 12 weeks for full remission (APA Guidelines for Major Depressive Disorder, 2010). Partial improvement is common in early phases. Make sure your patients understand that trajectory.

Decide on medication

Start medication if:

- The depression is moderate to severe
- There's functional impairment
- Suicidality is present
- Therapy alone has failed
- The patient prefers medication


For medication-naïve patients with uncomplicated depression, the ideal agent is effective, well tolerated, and free of sexual side effects, weight gain, and sedation. **Bupropion (Wellbutrin)** often checks all those boxes—

improves cognition (Gualtieri CT and Johnson LG. *MedGenMed*

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com



fluoxetine (Lexapro) and **sertraline (Zoloft)** are often first-line choices—both have minimal side effects and low risk of drug interactions.

See Table 2.1 for a list of clinical scenarios that often sway clinicians to choose a particular antidepressant, based on the clinical picture and the potential side effects of the medication.

TABLE 2-1. Choosing an Initial Antidepressant Based on Clinical Features

Clinical Scenario	First-Line Recommendations
Fatigue	Bupropion
Comorbid anxiety disorder	Escitalopram, sertraline
Insomnia, weight loss	Mirtazapine
Cognitive problems	Bupropion, vortioxetine
Sexual side effects are a dealbreaker	Bupropion, mirtazapine, or vortioxetine
Weight gain is a dealbreaker	Bupropion or fluoxetine
Chronic pain, fibromyalgia	Duloxetine
Smoking cessation	Bupropion
ADHD + depression	Bupropion
Bulimia	Fluoxetine
Atypical features (hypersomnia, etc.)	Monoamine oxidase inhibitors (MAOIs, often underused, but effective)
Child or adolescent	Fluoxetine

Titrate to a therapeutic dose, but don’t go too high. As we’ll see in Chapter 15, most antidepressants do not work better beyond the mid-range dose. Stay the course for 6–12 weeks unless intolerable side effects arise.

Psychotherapy: When, Why, and Which One

When therapy alone may be enough


Psychotherapy is reasonable as monotherapy for patients with mild to moderate depression. Predictors of a good psychotherapy response include secure attachment style, strong social supports, intact cognition, high dis-

and a high motivation for therapy.

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at www.thecarlatreport.com



Which therapy?

Cognitive behavioral therapy (CBT) is often upheld as the evidence-based therapy for depression, but other approaches are just as effective. Interpersonal psychotherapy (IPT) is an eclectic approach that was developed to mimic what the average therapist does in practice: problem-solving conflicts in relationships and processing grief. Psychodynamic therapy, mindfulness-based therapy, and behavioral activation also treat depression.

Therapy works best when it draws on the patient's strengths. For example, patients who lack relationships don't do as well with IPT, and those with difficulties in logical thought don't do as well with CBT (Sotsky SM et al, *Am J Psychiatry* 1991;148(8):997–1008).


Lifestyle Interventions

Lifestyle changes aren't optional add-ons. They're evidence-based components of depression treatment. In animal studies, antidepressants do not work if the animal is kept in isolation, unable to socialize, or if the researchers remove the hamster wheel so it can't exercise. In Chapter 14 we'll look at eight lifestyle changes that augment antidepressants.

Is This Depression Really Difficult to Treat?

Use a checklist approach:

- Were two or more antidepressants tried at adequate dose and duration (6–12 weeks)?
- Were they taken consistently?
- Were comorbidities addressed?
- Were lifestyle factors optimized?
- Was the diagnosis correct?



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)


Purchase your copy with full access online at
www.thecarlatreport.com

venlafaxine had only reached 75 mg. During treatment, he drank two to three glasses of wine nightly, had insomnia, and no rating scales were ever used. We restarted fluoxetine and titrated to 20 mg while initiating CBT and limiting alcohol. His depression rating scale (PHQ-9) dropped from 17 to 5 over 8 weeks.

Demetrius didn’t have TRD. He had *undertreated depression*.

Takeaway

Before escalating to augmentation or neuromodulation, take the time to build a solid treatment foundation. That means a proper diagnosis, a deliberate plan, and full-dose, full-length treatment with measured outcomes.



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

CHAPTER 3

Misdiagnosis

LET’S FACE IT—SOMETIMES THE FAILURE isn’t the antidepressant but our own diagnostic prowess. When a patient isn’t responding, consider these four common culprits:

- Missing bipolar disorder
- Missing psychiatric comorbidities
- Missing medical comorbidities
- Misjudging antidepressant response

Bipolar Disorder: The Great Pretender

Nearly half of patients with supposed “treatment-resistant depression” actually have undiagnosed bipolar disorder. The average patient with bipolar disorder waits seven years for the correct diagnosis, cycling through multiple failed antidepressant trials along the way.

Look for these clues:

- Early onset depression (before age 20)
- Family history of bipolar disorder
- History of agitation, irritability, or mood worsening on an antidepressant


We’ll dive deeper into this vexing diagnosis in Chapter 5.

Psychiatric Comorbidities: Depression

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com




The low mood may actually be a state of demoralization after years of untreated:

- ADHD (causing chronic underachievement)
- Anxiety disorders (leading to avoidance and a limited life)
- Personality disorders (creating relationship turmoil)
- Addiction (with its cascade of social and medical consequences)

Some comorbidities respond better to specific medications:

- **OCD**—Clomipramine (Anafranil) or high-dose selective serotonin reuptake inhibitors (SSRIs)—typically twice the dose needed for depression alone).
- **Anxiety disorders**—Medium to high doses of SSRIs or serotonin-norepinephrine reuptake inhibitor (SNRIs)—aim for the upper range of the optimal depression dose (see Chapter 15 for dosing tables).
- **ADHD**—Bupropion (Wellbutrin) or viloxazine (marketed as Qelbree for ADHD in the US but approved for depression elsewhere).
- **Bulimia and binge eating**—Fluoxetine (Prozac, FDA-approved for bulimia at 60 mg/day), sertraline (Zoloft, 50–100 mg), or duloxetine (Cymbalta, 60–120 mg). Avoid bupropion due to increased seizure risk in bulimia.
- **Substance use disorders**—Often require specialized treatment alongside depression care. Even moderate alcohol use can sabotage antidepressant response. Cannabis use correlates with poorer outcomes in depression treatment, particularly with daily use (Nunes EV et al, *Am J Psychiatry* 2023;180(3):179–181; Bahorik AL et al, *J Affect Disord* 2017;213:168–171). Consider asking:
 - “Many people use substances to cope with depression. What have you found helpful?”
 - “When did you last go for at least a month without alcohol or cannabis?”



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

CHAPTER 12

The Psychology of Depression

HOPELESS, UNMOTIVATED, FORGETFUL. The symptoms of depression get in the way of recovery. Clinicians need to be on alert for these problems, gently pointing them out when they get in the way of care. Ideally, patients will see that it is their depression acting up when, for example, thoughts of worthlessness cause them to miss appointments. In chronic depression, the symptoms can weave their way into personality. For these patients, depression is who they are, not what they have. Gaining perspective on their symptoms is difficult, but not impossible.

Hopelessness

Patients often give up on lifestyle change or neglect to fill their medication prescriptions out of hopelessness, an overarching feeling that nothing will work. Optimism is the antidote, but unless it is balanced with realism, it can backfire. Excessive optimism inspires mistrust, especially among those with chronic depression.

Hopelessness is contagious. I keep a long list of options for depression on my desk to ensure that I don't fall into the countertransference trap of giving up and doing nothing.


Passivity

Passivity begins from the moment the patient enters the room and asks

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com






FIGURE 12-1. Stress and depression have caused the neurons in this picture to shrink back, forming fewer dendritic connections.





FIGURE 12-2. The neurons have grown and formed more connections after treatment with neuroprotective agents like medication, psychotherapy, exercise, and other lifestyle changes.

and view patients as dangerous (Kemp JJ et al, *Behav Res Ther* 2014;56:47–52; Loughman A and Haslam N, *Cogn Res Princ Implic* 2018;3(1):43).

One way to overcome this dilemma is to emphasize how lifestyle



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Treatment Menus


TO ENHANCE COLLABORATION, present your patient with a menu of reasonable options. Keep it brief, 3–4 treatment steps that are likely to work. Aim for variety. Instead of presenting three antipsychotics, choose one treatment that is tolerable, one that is very effective, and one from the natural or lifestyle side. In the lists below, I've divided the treatments in this book into approximate categories to get you started.

Favorable Tolerability

- Celecoxib
- Eszopiclone
- Light Therapy
- L-methylfolate
- Omega-3 fatty acids
- Pramipexole
- Probiotics
- Psychotherapy
- Thyroid
- Transcranial magnetic stimulation (TMS)

Large Effect Size

- Electroconvulsive therapy (ECT)
- Ketamines
- Light therapy



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

- Pramipexole
- SNT (Saint TMS)

For Prevention in Recurrent Depression

- Exercise
- Lithium
- Natural therapies for deficiency states in chapters 35–40 (possibly)
- Pramipexole
- Psychotherapy

For Anxious Depression


- Benzodiazepine augmentation
- Buspirone augmentation
- Eszopiclone augmentation
- Ketamines
- MAOI switch
- Mirtazapine augmentation
- Probiotics
- Quetiapine
- TMS
- Zuranolone (for postpartum)

For Unipolar Depression with Mixed Features

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com



- Amantadine (possibly)
- ECT
- Ketamines
- Lamotrigine (possibly)

- Light therapy
- Lithium
- Omega-3 fatty acids
- Pramipexole
- Psychotherapy
- Second generation antipsychotics
- Thyroid
- TMS

For Psychotic Depression

- Antipsychotic augmentation (high dose)
- ECT
- Lithium

For Vascular Depression

- ECT
- Nimodipine
- TMS


For Inflammatory Depression

- Bupropion
- Citalopram

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com



For Depression with Trauma

- Psychotherapy
- Prazosin (Minipress) augmentation

Index

Note: This is not a comprehensive index. Page references have been limited to the most relevant discussions of each topic. **Bold page numbers** indicate the beginning of a chapter or major section where the topic is introduced. Cross-references and related terms are included where useful to help readers locate connected material efficiently.

A

Acceptance and commitment therapy (ACT), 241

ADHD, comorbid with depression, 7, 16, 107, 194, 316

Adverse childhood experiences. *See* Childhood trauma

Age of onset, **15**, 31, 36, 37, 42, 43, 56-57, 149

Agomelatine, 128

Akathisia, **43**, 158, 160, 162, 163, 165

Alcohol use, **16**, 59, 109, 160, 164

Alkaline phosphatase, 243

Allopregnanolone, 80, 234

Alpha-2 agonists (clonidine, guanfacine), 127

Amantadine (Symmetrel), **119**, 140, 141, 165, 167

Amiloride, 151, 153, 154

Anhedonia, **61**, 62, 64, 72, 170

Antipsychotics, 154

- Augmentation strategy, 47, 53-54, 78, 118-119, 140-144, 156-169
- First-generation (typical), 54, 157, 167
- Second-generation (atypical), **41**, 46, 48, 77, 118, 120
- Individual agents: *See* Aripiprazole; Brexpiprazole; Cariprazine; Lumateperone; Lurasidone; Olanzapine; Quetiapine; Risperidone

- Second-line, 119, 141, 177-187

- Third-line, 119, 141, 189-203

- vs. switching, 117-118

Auvelity (bupropion-dextromethorphan), 206, **217-220**

Autoimmune conditions, 153, 180-181

B

Bacterial considerations, 110, 200-203

Behavioral activation, 8, 98, 101, 102, 103, 120, **209**, 210

Benzodiazepines, 78, 127, 163, 165, **208-212**, 214, 227, 229, 283, 297, 304, 312-314

- Alprazolam (Xanax), 78, 208-212, 236

- Clonazepam (Klonopin), 210, 211

- Lorazepam, 165

Bipolar disorder, **15**, 27-29, 36-37, 42, 49, 52, 60, 71, 145

- Diagnosis and screening, 5, 30-40

- Bipolar I, 28, 34, 56

- Bipolar II, 28, 30, 31, 76

- Bipolar features/soft bipolar, 3, 4, 49, 145-146, 172


- Bipolarity Index, 29, 36-39, 40-41

- BSDS (Bipolar Spectrum Diagnostic Scale), 30, 31-32

- Cyclothymic disorder, 29-30, 37

- Family history, 15, 39-40

- Postpartum, 237-238



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Brexanolone (Zulresso), 233, 235

Buprenorphine (Suboxone), 126

Bupropion (Wellbutrin), 6, 7, 16, 47, 54

Buspiron (BuSpar), 78-79, 81, 119, 127, 140

C

Cariprazine (Vraylar), 41, 156, 160

CBASP (cognitive behavioral analysis system of psychotherapy), 68-69

CBT (Cognitive behavioral therapy), 8, 9, 22, 47, 64

- CBT-insomnia, 47, 64, 71-72, 105-107

Celecoxib (Celebrex). *See* NSAIDs/COX-2 inhibitors

Cerebrovascular disease. *See* Vascular depression

Childhood trauma, 4, 62, 68, 94

Children and adolescents, 7, 42-43, 149, 158

Chronic depression, 3, 7, 66, 87, 90, 96-99, 191

Chronic illness management, 96-99

Chronic pain, 7, 17, 132, 137, 196

Circadian rhythms, 47, 81, 103-104, 106, 147, 252

Clinical assessment, 3, 4, 5, 9, 19-23

- FAST (Functional Assessment Short Test), 22-23
- General Symptom Scale, 21-22
- MoCA (Montreal Cognitive Assessment), 22
- Patient Health Questionnaire (PHQ-2, PHQ-9), 9, 21, 55
- Rating scales, 9, 20-23, 30-32, 43, 55, 66-67
- THINC-it app, 22

Cognitive impairment, 5, 6, 7, 22, 52, 56-60

- Validities, 3, 4, 5-8, 21

Cytokines, 62, 147, 185, 201

D

d-Cycloserine, 119, 140, 141, 195-199

DBT (dialectical behavior therapy), 47, 70

Default mode network, 103, 107, 224

Delusions, 37, 49-52, 55, 237

Dementia, 17, 22, 52, 56, 59, 135, 149, 152, 168, 220, 273

Deplin. *See* L-methylfolate

Deprescribing, 42, 46, 119

- Amphetamines, 314-316
- Anticonvulsants, 318-319
- Benzodiazepines, 312-314
- Bupropion, 308-309
- Bupirone and Gepirone
- Methylphenidate, 314-316
- Modafinils, 316-318
- Mirtazapine, 310-311
- SSRIs 306-308
- SNRIs, 306-307


Depression, 3, 5

- Atypical features, 5, 7, 37, 74-79, 81, 122-124, 129
- Chronic, 3, 7, 66, 87, 90
- Inflammatory, 23, 61-65, 102, 172-173, 184-187, 200-203
- Melancholic features, 5, 79, 81, 82, 117
- Mixed features, 23, 29, 41, 42, 61
- Postpartum, 37, 61, 62, 82, 184-185, 233-237, 297
- Psychotic, 23, 76, 80, 157-158, 222, 223, 240-285
- Recurrent, 4, 7, 37, 38, 39
- Seasonal, 79-80, 82, 104
- Treatment-resistant (TRD), 3, 4, 8,

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com



Dissociation, 219, 226, 228, 229, 304, 305

Dopamine agonists, **62**, 64, 65, 93, 123

- Pramipexole (Mirapex), **3**, 41, 62, 64, 65
- Other agents, 166, 172

Drug interactions, **6**, 46, 132, 136, 147

DSM- **5**, 5, 28, 30-34

E

Eating disorders, 15, 16, 151, 258

ECT (Electroconvulsive therapy), **46**, 53, 55, 59, 60

Elderly patients. *See* Geriatric patients

Endocrine disorders, 17, 110. *See also* Thyroid

EPA (eicosapentaenoic acid). *See*

Omega-3 fatty acids

Esketamine (Spravato), **81**, 127, 140, 159

Eszopiclone, **213**, 216

Exercise, **8**, 59, 61, 63, 64

Extrapyramidal symptoms, 154, 166, 168.

See also Akathisia; Tardive dyskinesia

F

Family history, **15**, 29, 36, 38, 43

Folate/L-methylfolate (Deplin), **17**, 18, 63, 64, 65

Food interactions (MAOIs), 122, 124, 126, 129-130

Functional impairment, 6, 57, 97-99

G

GABA/GABAA receptor, 147, 162, 209, 214, 234

Gabapentin (Neurontin), 151, 173

Gastrointestinal effects, **135**, 136, 150, 151, 164, 186, 266

H

Hallucinations, **37**, 43, 165, 193

Hepatotoxicity, **125**, 136, 165, 186, 187

hs-CRP (high-sensitivity C-reactive protein), **18**, 61-64

Hypomanic/manic symptoms, 28-40, 44-45

- Antidepressant-induced, 122, 125, 129, 132
- Elevated confidence, **33**, **44**
- Elevated energy, **33**, **35**, **45**
- Elevated mood, **31**, **33**, **37**, **44**
- Hyperactivity, **33**, **44**
- Racing thoughts, **31**, **33**, **35**, **36**

Hypothyroidism, **18**, 149, 153, 180, 181

I

Impulsive behavior, **30**, **33**, **36**, **38**, **39**

Inflammatory depression, 23, **61-65**, 102, 172-173, 184-187, 200-203

Insomnia, **6**, **7**, **43**, **61**, **82**, 105-107, 157

Insulin resistance, 17, 164, 165-166

Interpersonal psychotherapy (IPT), **8**, 93, 100-101

Irritability, **5**, **15**, **21**, **31**, **33**, 264, 294

K


Ketamine, **207**, 222

- **207**, 222
- Montreal Model, 207, 223-224, 229

L

Laboratory monitoring, **149**, 152, 153, 181, 186

- Alkaline phosphatase, 243
- Complete blood count (CBC), 17, 186



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Lamotrigine (Lamictal), 41, 46, 152, 192

Lifestyle interventions, 8, 47, 59, 81, 87

Light therapy, 3, 47, 80, 81, 82

Lithium, 3, 41, 46, 54, 55

- Lithium orotate, 154-155
- Side effect management, 150-151
- Toxicity, 140, 145, 146, 149, 150, 153-154

Lumateperone (Caplyta), 41, 46, 48, 81, 126

Lurasidone (Latuda), 41, 46, 48, 81

M

Maintenance treatment, 47, 132, 145, 149, 158

MAOIs (monoamine oxidase inhibitors), 7, 75, 76, 77, 81

- Drug interactions, 126-128
- Food interactions/tyramine, 122, 124, 126, 129-130
- Individual agents: Isocarboxazid (Marplan), 123, 124, 125, 128
- Serotonin syndrome risk, 122, 125-129

MDMA, 43, 127, 239, 243

Measurement-based care, 20-23

Mediterranean diet, 59, 63, 64, 65, 88

Melancholic depression, 5, 79, 81, 82, 117

Metabolic syndrome, 157, 163-164, 165, 166, 168, 169

- Metformin for, 163, 164, 165, 166

Methylphenidate (Ritalin, Concerta), 59, 119, 127, 128

Microbiome, gut, 164, 165, 201, 202, 203

Mindfulness, 8, 48, 63, 64, 107

Minocycline (Minocin), 62, 64, 65, 119, 140

Mirtazapine (Remeron), 7, 20, 54, 78, 81

Mixed depression, 23, 29, 41, 42, 44-48, 61

Naltrexone (Revia), 164, 165, 225, 229

Nausea management, 60, 124, 125, 150

Nephrogenic diabetes insipidus (NDI), 149, 151, 152-153

Neuroinflammation. *See* Inflammatory depression

Neuroleptic malignant syndrome, 168

Neuroprotection, 88, 102, 107, 110, 133

Nightmares/night terrors, 69, 71, 72, 73

- Prazosin (Minipress) for, 72-73

Nimodipine (Nimotop), 59-60, 151

NMDA receptor, 192, 197, 218, 225

NSAIDs/COX- 2, 62, 64, 65, 154, 184, 186

Nutritional deficiencies, 17-18. *See also* Folate; Omega-3 fatty acids; Vitamin D

O

Obesity, 17, 61, 62, 63, 64

Obsessive-compulsive disorder (OCD), 15-16, 38, 132, 133

- Postpartum, 237

Olanzapine (Zyprexa), 53, 54, 157, 158, 159

- Olanzapine-fluoxetine (Symbyax), 41, 54, 140, 141, 156
- Olanzapine-samidorphan (Lybalvi), 163-164, 165

Omega-3 fatty acids (EPA/DHA), 62-63, 64, 65, 107, 151

Opioids, 126, 127, 163, 164

- Mu-opioid receptor, 225

Orthostatic hypotension, 124, 125, 127, 128, 136

P

Pain, chronic, 7, 17, 132, 137, 185


Parkinson's disease, 17, 52, 93, 123, 170

Personality disorders, 7, 16, 30, 38

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com



- Complex PTSD, 69-70, 73
- Trauma-focused therapy, 70, 73
- Traumatic Life Events screener, 66-67

Pramipexole (Mirapex). *See* Dopamine agonists

Prazosin (Minipress), 72-73

Probiotics, **3**, 62, 82, 141, 151

Prolactin elevation, **161**, 162, 163, 165, 166

Psychedelics, 207, 239-243

- Classic (psilocybin, LSD), 239-243
- MDMA, 43, 127, 239, 243
- Psychedelic-assisted therapy, 224, 239

Psychodynamic therapy, 8, 68, 120

Psychological mechanisms, 87-95

- Countertransference, 87, 91-92, 94
- Placebo effect, 92-94
- Secondary gains, 90
- Therapeutic alliance, 93-94, 148
- Transference, 90-91, 94

Psychosis, **42**, 130, 165, 172, 174

- Postpartum, 237
- Psychotic depression, **23**, 76, 80, 132, 157

Psychotherapy, 64, 68, 70, 73

Q

QTc prolongation, 166, 168

Quetiapine (Seroquel), **41**, 53, 79, 81, 145

R

Rapid-acting treatments, 78, 141, 157,

S

Screening instruments. *See* Assessment

Seasonal affective disorder, 79-80, 82, 104, 251

Sedation, **6**, 93, 125

Seizures, **6**, 16, 195

Serotonin receptors

- 5-HT1A, 162, 309
- 5-HT2A, 162, 241
- 5-HT3, 150

Serotonin syndrome, **122**, 125-129, 219

Serotonin transporter (SERT), 19-20, 42, 185

Sexual dysfunction, **6**, 7, 124, 125, 135


Sleep, **6**, 21, 31, 33, 45

- Blue light management, 47-48, 81, 104-105
- CBT-insomnia, 47, 64, 72, 105-107
- Circadian rhythms, 47, 81, 103-104, 106, 147
- Sleep apnea, 17, 59, 72, 73, 101
- Sleep hygiene, 63, 105-106

SNRIs (serotonin-norepinephrine reuptake inhibitors), **16**, 41, 70, 77, 127

- Desvenlafaxine (Pristiq), 118, 120, 121, 132
- Duloxetine (Cymbalta), 7, 16, 43, 120, 132
- Venlafaxine, 132

Social support/isolation, 7, 8, 22, 36, 88



Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

Renal function/toxicity, **149**, 155, 165, 173, 175

Restless leg syndrome (RLS), 171, 172, 173, 174, 175

Risperidone (Risperdal), **53**, 158, 161, 162, 163

Stimulants, 119, 127, 128, 140, 170, 172.

See also Methylphenidate

Substance use disorders, **15**, 16, 30, 38, 39

Suicidal ideation/risk, **4**, 6, 42, 43

Switching antidepressants, 3, 117-118, 121, 132, 162

T

Tardive dyskinesia, **150**, 156, 157, 158, 164-165

Therapeutic alliance, 93-94, 148

Thyroid augmentation/dysfunction, **17**, 18, 117, 119, 128

- Antithyroid antibodies, 181
- Hypothyroidism, **18**, 149, 153, 180, 181
- Laboratory monitoring, 17, 149, 153, 181, 183
- Levothyroxine (Synthroid, T4), 153, 180, 181
- Subclinical hypothyroidism, 17, 153, 181, 183
- Supraphysiologic dosing, 180, 182
- Triiodothyronine (T3), 128, 180, 181, 182

TMS (Transcranial magnetic stimulation), **46**, 53, 58, 59, 60

Transference, 90-91, 94

Trauma, 6, 15, 23, 66-73. *See also* PTSD

Trazodone (Desyrel), **43**, 47, 81, 120, 127

Tricyclic antidepressants (TCAs), **19**, 42, 54, 62, 65

- Amitriptyline, **128**, 132, 133, 134, 135
- Clomipramine (Anafranil), **16**, 127, 128, 132, 133
- Desipramine, **128**, 133, 134, 135
- Doxepin, 133, 134

- Imipramine (Tofranil), **75**, 93, 94, 127, 128
- Nortriptyline (Pamelor), **62**, 64, 132-137
- Protriptyline, 134, 137
- Secondary vs. tertiary amines, 133, 134, 136, 137
- Side effect management, 135-136

U

Unipolar depression, **27**, 28, 30, 37, 38

V

Valproate (Depakote), 46, 152

Vascular depression, 3, 23, 56-60, 151

Vitamin D, 108, 247-249, 261-263

Vitamins, B complex, **17**, 108, 125, 128, 151

W

Weight gain, 159-166

- Management strategies, 163-166

Withdrawal symptoms, **206**, 211, 219, 222, 227

Z

Z-hypnotics, 214, 215, 235. *See also* Eszopiclone

Zuranolone (Zurzuvae), 206, 209, 233-238

Sample Pages

Difficult To Treat Depression: A Carlat Guide (2026)

Purchase your copy with full access online at
www.thecarlatreport.com

